Clinical Trial Results:
THOR - Tübingen Choroideremia gene therapy trial open label Phase 2 clinical trial using an adeno-associated viral vector (AAV2) encoding Rab-escort protein 1 (REP1)
Summary
|
|
EudraCT number |
2014-005004-21 |
Trial protocol |
DE |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
09 Aug 2022
|
First version publication date |
16 Jul 2022
|
Other versions |
v1 |
Version creation reason |
|
Summary report(s) |
Statement Final report Safety report |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.